Hidden in Plain Sight: Autosomal Dominant Tubulointerstitial Kidney Disease

Presented by Anthony Bleyer, MD, MS (Professor Nephrology at Wake Forest University School of Medicine) this presentation covered genetics of ADTKD, biology and mechanisms, Wake Forrest registry description, and unmet drug development needs. This webinar was brought to you by Critical Path Institute's Rare and Orphan Disease Program's Rare Disease Cures Accelerator-Data and Analytics Platform and its Polycystic Kidney Disease Outcomes Consortium teams.
SUBSCRIBE to C-Path's UA-cam Channel Now ►► / criticalpathinstitute
FOLLOW C-Path:
►LinkedIn: / c-path
►Facebook: / cpathinstitute
►Twitter: CPathInstitute?re
About Critical Path Institute
C-Path is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
#CPath #drugdiscovery #researchgrants #globalhealth #drugdevelopment #datasharing #researchfunding #raredisease #academicresearch #regulatoryscience #globalhealth #consortia #collaboration #FDA #EMA #T1D #Parkinsons #Alzheimers #PKD #Duchenne #ALS #biomarker #RDCA-DAP #PKDOC #ROD